|
13 Sep 2020
|
Brokerage Research Reports
|
Prabhudas Lilladhar
|
|
|
|
|
Strategy Note
|
|
|
Mid/Small caps could witness a shift of Rs120bn and Rs220bn to Mid/small caps till the date of compliance in Jan2021 Nifty increased by 9.5% upto Jan 18 while...
|
|
13 Sep 2020
|
Brokerage Research Reports
|
Prabhudas Lilladhar
|
|
|
|
|
Strategy Note
|
|
|
Mid/Small caps could witness a shift of Rs120bn and Rs220bn to Mid/small caps till the date of compliance in Jan2021 Nifty increased by 9.5% upto Jan 18 while...
|
|
11 Sep 2020
|
Brokerage Research Reports
|
Prabhudas Lilladhar
|
|
|
|
|
Sell
|
|
|
With 3.9% YoY decline in IPM in this fiscal already, India formulations focused companies may need to revise their growth estimates downward for FY21E. While Indian economy heads towards gradual re-opening, IPM growth hasn't witnessed much revival even with no restriction imposed on the industry. Apart from few therapies like Cardiac and Anti-Diabetic, rest have been on a declining trend or lacked consistent growth. India formulations sales declined (YoY) for majority stakeholders. We expect similar trend could follow in 2QFY21E as well as key players have reported decline in sales in first five...
|
|
11 Sep 2020
|
Brokerage Research Reports
|
Prabhudas Lilladhar
|
|
|
|
|
Sell
|
|
|
With 3.9% YoY decline in IPM in this fiscal already, India formulations focused companies may need to revise their growth estimates downward for FY21E. While Indian economy heads towards gradual re-opening, IPM growth hasn't witnessed much revival even with no restriction imposed on the industry. Apart from few therapies like Cardiac and Anti-Diabetic, rest have been on a declining trend or lacked consistent growth. India formulations sales declined (YoY) for majority stakeholders. We expect similar trend could follow in 2QFY21E as well as key players have reported decline in sales in first five...
|
|
07 Sep 2020
|
Brokerage Research Reports
|
BOB Capital Markets Ltd.
|
|
|
|
|
|
|
|
Key takeaways from our recent interaction with the management of Greenpanel Industries (GREENP).
|
|
07 Sep 2020
|
Brokerage Research Reports
|
IDBI Capital
|
|
|
|
|
|
|
|
|
|
07 Sep 2020
|
Brokerage Research Reports
|
IDBI Capital
|
|
|
|
|
|
|
|
|
|
03 Sep 2020
|
Brokerage Research Reports
|
Karvy
|
|
|
|
|
Economy Update
|
|
|
Credit growth continues to remain subdued despite availability of ample liquidity with banks.
|
|
03 Sep 2020
|
Brokerage Research Reports
|
ICICI Securities Limited
|
|
|
|
|
Hold
|
|
|
Amid Covid-19 ARC business reported healthy AUM growth of 53.5% QoQ at | 66300 crore and recoveries at | 470 crore. For AMC business, AUM was at | 29400 crore with gross revenue at | 25 crore (yield at 0.08%). Higher operating costs marred EAML's PAT growth and led it to come in at | 2 crore....
|
|
03 Sep 2020
|
Brokerage Research Reports
|
Chola Wealth Direct
|
|
|
|
|
|
|
|
Background: Indian Bank features among the mid-sized banks in the public sector space. As of 1QFY21, the bank had business of about 8.5tn operating through a network of 6062 branches. Prior to amalgamation with Allahabad bank, Indian Bank's footprint was largely skewed towards the southern states of Tamil Nadu, Karnataka, Andhra Pradesh and Kerala. Now the combined entity has a stronger presence in Central and Eastern states of India too. With RoA of ~0.26%, the bank features amongst the most profitable banks in the PSU space. The bank has...
|